Pain Management Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Pain Management Industry is Segmented by Mode of Pain Management (Drugs (Opioids and Non-narcotic Analgesics (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-depressants, and Other Non-narcotic Analgesics)), Devices (Neurostimulation Devices (Transcutaneous Electrical Nerve Stimulation (TENS) Devices and Brain and Spinal Cord Stimulation (SCS) Devices)), and Analgesics Infusion Pumps (Intrathecal Infusion Pumps and External Infusion Pumps)), by Application (Neuropathic Pain, Cancer Pain, Facial Pain and Migraine, Musculoskeletal Pain, and Other Applications), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Pain Management Market Size

Pain Management Market  Summary
share button
Study Period 2018 - 2028
Market Size (2023) USD 75.41 Billion
Market Size (2028) USD 89.96 Billion
CAGR (2023 - 2028) 3.59 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Pain Management Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Pain Management Market Analysis

The Pain Management Market size is expected to grow from USD 75.41 billion in 2023 to USD 89.96 billion by 2028, at a CAGR of 3.59% during the forecast period (2023-2028).

The COVID-19 pandemic has impacted healthcare systems across the world. Health agencies were involved in containing coronavirus transmission through lockdown norms, and most elective and non-urgent surgeries were postponed globally. As per the Indian Journal of Anaesthesia 2020, COVID-19 negatively impacted pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also published guidelines on anesthesia and intensive care practices. Also, the Journal of Pain Medicine suggested that epidural nonsteroid injections for radicular pain can be considered in patients who are already immunosuppressed and at high risk of SARS-CoV-2 infection and complications. As per the April 2022 data published by PubMed, it was observed that people across the United States and Canada suffering from chronic pain witnessed a significant increase in pain during the pandemic. However, following the pandemic, effective pain management is practiced among people suffering from chronic pain, as restrictions on non-essential hospital visits are lifted. Hence, it is observed that the current market has reached a pre-pandemic nature.

The well-established business of using painkiller medications as the first line of treatment has significantly contributed to the growth of the pain management market. However, in recent years, the growing reliance on their long-term use, as well as a better understanding of their side effects, has led to an increase in the use of device-based pain management therapies. Post-operative pain is one of the most common. The cost of monitoring and treating adverse effects creates a significant demand for pain management drugs and devices.

The current market is gradually adopting more non-opioid medications to suppress the addiction to opioids and other well-established painkillers on the market. Several non-opioid drugs with mechanisms of action are currently in the early and late stages of development. The regulatory authorities in multiple countries are shifting to alternative approaches, thus fast-tracking those drugs to market approval. The shift is expected to be gradual. Thus, pain management has desirable growth prospects during the forecast period.

The increasing aging population globally is expected to drive the market's growth, as the prevalence of chronic pain is relatively high among the geriatric population and is considered an independent risk factor for mortality. The increasing number of product launches is also expected to drive the market. For instance, in Octover 2021, Esteve Pharmaceuticals received approval from the US FDA for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Thus, due to such factors, the pain management market is expected to grow significantly over the forecast period.

However, high procedural and purchase costs of pain management devices can restrain the market's growth.

Pain Management Market Trends

This section covers the major market trends shaping the Pain Management Market according to our research experts:

Facial Pain and Migraine Segment is Expected to Exhibit a Significant Growth Rate During the Forecast Period

Headache and facial pain are the few frequent complaints in the emergency and outpatient setting. Most patients who present themselves with headaches have one of the following three main headache syndromes: migraine, cluster headache, or tension headache.

The Migraine Research Foundation updated in 2021 that migraine is an extraordinarily prevalent neurological disease, affecting about 39 million men, women, and children in the United States and 1 billion worldwide. Migraine is considered the third-most prevalent illness in the world. According to the Cleveland Clinic update in 2021, migraine is also the sixth-most disabling illness in the world. For every 10 seconds, someone in the United States goes to the emergency room complaining of a headache, and approximately 1.2 million visits are for acute migraine attacks. Hence, the high prevalence of migraine is expected to propel the growth of the pain management market in the coming years.

Furthermore, the burden of headaches and migraine is found to be the same across the world, and every day, the percentage of people suffering from migraine/headaches increases. For instance, according to the article published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, the high prevalence of migraine is expected to boost the migraine therapeutics market. Moreover, several companies are launching new products in the market, leading to the growth of the segment studied. In February 2022, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. Hence, such new launches and high prevalence of pain, the segment is expected to witness a strong growth in coming years.

In addition, the increasing burden of cancer is also contributing largely to facial pain and headache which is a fueling factor for the segment growth.

Pain Management Market - Estimated Number of New Cases of Cancer for Both Sexes, Aged Between 0-85+ (in Million), Global,  2025-2050

North America Captured the Largest Market Share and is Expected to Retain its Dominance During the Forecast Period

North America holds the largest share of the pain management market, with the United States being the most significant contributor to its revenue. Factors such as increasing demand for long-term pain management from the geriatric population and developments in the pain management field are expected to boost the market growth in North America.

Moreover, according to PubMed data from 2022, the prevalence of chronic pain in Americans is increasing. Every year, one out of five people suffers from chronic pain in the region. Since it is one of the most common chronic conditions in the United States, there is a growing demand for pain management across the country. Furthermore, according to the recommendations provided by the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain procedures may induce immune suppression, which is very critical as it minimizes the chances of fighting several viral infections. Hence, all the aforesaid factors are expected to increase the demand for pain management devices and drugs over the forecast period.

Overall, the US pain management market is considered highly competitive, primarily due to the significant presence of pain specialist physicians, the increasing trend of product approvals from the FDA, and the robust infrastructure for providing pain management services to patients. For instance, in November 2021, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. formed a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the United States and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. Thus, the market is expected to grow significantly in North America over the forecast period.

Pain Management Market  - Growth Rate by Region

Pain Management Industry Overview

The pain management market is highly competitive and consists of several major players. The existing players in the pain management market employ strong competitive strategies, leading to intense competition. Some of the key players in the market are Abbott Laboratories, Johnson & Johnson, Baxter International Inc. (Avante Health Solutions), Becton, Dickinson and Company, and Boston Scientific Corporation, among others.

Pain Management Market Leaders

  1. Abbott Laboratories

  2. Becton, Dickinson and Company

  3. Boston Scientific Corporation

  4. Johnson and Johnson

  5. Baxter International Inc. (Avante Health Solutions)

*Disclaimer: Major Players sorted in no particular order

Pain Management Market Concentration

Pain Management Market News

  • October 2022: Parker Laboratories Inc., which develops, manufactures, and sells pain relief creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants, is expanding its analgesics line. The company has added Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream to its HelixTM line.
  • September 2022: Compass Group Equity Partners, a St. Louis-based private equity firm, announced a strategic partnership with Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"), a Memphis-based interventional pain management practice serving patients in Tennessee and Mississippi.
  • July 2021: Venus Remedies Limited has launched a consumer healthcare division that will offer various products for pain management.
  • January 2021: Boston Scientific Corporation launched the WaveWriter Alpha, a portfolio of spinal cord stimulator (SCS) systems that combine therapy options for personalized pain relief.

Pain Management Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for Long-term Pain Management from the Geriatric Population

      2. 4.2.2 Proven Efficacy of Pain Management Devices for the Treatment of Chronic Pain

      3. 4.2.3 Development of Novel Pain Management Devices and Techniques

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness About the Availability and Use of Pain Management Devices

      2. 4.3.2 High Procedural and Purchase Cost of Pain Management Devices

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 BY Mode of Pain Management

      1. 5.1.1 Drugs

        1. 5.1.1.1 Opioids

        2. 5.1.1.2 Non-narcotic Analgesics

          1. 5.1.1.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

          2. 5.1.1.2.2 Anesthetics

          3. 5.1.1.2.3 Anticonvulsants

          4. 5.1.1.2.4 Anti-depressants

          5. 5.1.1.2.5 Other Non-narcotic Analgesics

      2. 5.1.2 Devices

        1. 5.1.2.1 Neurostimulation Devices

          1. 5.1.2.1.1 Transcutaneous Electrical Nerve Stimulation (TENS) Devices

          2. 5.1.2.1.2 Brain and Spinal Cord Stimulation (SCS) Devices

        2. 5.1.2.2 Analgesic Infusion Pumps

          1. 5.1.2.2.1 Intrathecal Infusion Pumps

          2. 5.1.2.2.2 External Infusion Pumps

    2. 5.2 By Application

      1. 5.2.1 Neuropathic Pain

      2. 5.2.2 Cancer Pain

      3. 5.2.3 Facial Pain and Migraine

      4. 5.2.4 Musculoskeletal Pain

      5. 5.2.5 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Baxter International Inc. (Avante Health Solutions)

      3. 6.1.3 Becton, Dickinson and Company

      4. 6.1.4 Boston Scientific Corporation

      5. 6.1.5 Fresenius SE & Co. KGaA

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Medtronic PLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Endo International PLC

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

Pain Management Industry Segmentation

Pain is an unpleasant sensation in the body due to ongoing or impending tissue damage. Pain management includes therapies, drugs, and devices that help alleviate the pain. The pain management market is segmented by mode of pain management (drugs and devices), drugs is further sub-segmented by (opioids and non-narcotic analgesics), and non-narcotic is sub-sub-segmented by (non-steroidal anti-inflammatory drugs, anesthetics, anticonvulsants, anti-depressants, and other non-narcotic analgesics), devices is sub-segmented by (neurostimulation devices and analgesic infusion pumps), neurostimulation devices is sub-sub-segmented by (transcutaneous electrical nerve stimulation devices and brain and spinal cord stimulation devices), and analgesics infusion pumps is sub-sub-segmented by (intrathecal infusion pumps and external infusion pumps), by application (neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, and other applications), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

BY Mode of Pain Management
Drugs
Opioids
Non-narcotic Analgesics
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Anesthetics
Anticonvulsants
Anti-depressants
Other Non-narcotic Analgesics
Devices
Neurostimulation Devices
Transcutaneous Electrical Nerve Stimulation (TENS) Devices
Brain and Spinal Cord Stimulation (SCS) Devices
Analgesic Infusion Pumps
Intrathecal Infusion Pumps
External Infusion Pumps
By Application
Neuropathic Pain
Cancer Pain
Facial Pain and Migraine
Musculoskeletal Pain
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Pain Management Market Research FAQs

The Pain Management Market size is expected to reach USD 75,413.79 million in 2023 and grow at a CAGR of 3.59% to reach USD 89,958.03 million by 2028.

In 2023, the Pain Management Market size is expected to reach USD 75,413.79 million.

Abbott Laboratories, Becton, Dickinson and Company, Boston Scientific Corporation, Johnson and Johnson and Baxter International Inc. (Avante Health Solutions) are the major companies operating in the Pain Management Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in the Pain Management Market.

Pain Management Industry Report

Statistics for the 2023 Pain Management market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pain Management analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!